论文部分内容阅读
目的评价拉司太特单药治疗晚期老年非小细胞肺癌(NSCLC)的疗效和安全性。方法30例晚期非小细胞肺癌患者采用拉司太特口服25mg,每日2次,服药21d,间隔1周后重复,共3周期,并进行评价。治疗前、治疗后2个月及3个月分别用肺癌患者生存质量测定量表FACT-L中文版进行生活质量(QOL)测评。结果30例患者均完成3个周期化疗,部分缓解7例,总有效率23.3%。Ⅲ/Ⅳ度白细胞减少发生率16.7%,其他副反应轻微。结论拉司太特治疗晚期非小细胞肺癌有一定疗效,但要注意白细胞下降。
OBJECTIVE: To evaluate the efficacy and safety of lasitome monotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients. Methods Thirty patients with advanced non-small cell lung cancer received oral administration of 25 mg salbutamol twice a day for 21 days, followed by 1 week interval and repeated for 3 cycles. Quality of life (QOL) was assessed by FACT-L Chinese version before treatment, 2 months and 3 months after treatment, respectively. Results All the 30 patients completed 3 cycles of chemotherapy, 7 of them partially relieved, with a total effective rate of 23.3%. Ⅲ / Ⅳ degree of leukopenia incidence of 16.7%, other minor side effects. Conclusion Lasoside treatment of advanced non-small cell lung cancer have a certain effect, but pay attention to leukopenia.